12-15-2017

The Role of MAPK and SCF in the Destruction of Med13 in Cyclin C Mediated Cell Death

David C Stieg
Rowan University School of Osteopathic Medicine

Stephen D Willis
Rowan University School of Osteopathic Medicine

Joseph Scuorzo
Rowan University School of Osteopathic Medicine

Mia Song
Rowan University School of Osteopathic Medicine

Vidyaramanan Ganesan
Rowan University School of Osteopathic Medicine

Recommended Citation

Stieg DC, Willis SD, Scuorzo J, Song M, Ganesan V, Strich R, Cooper KF. The role of MAPK and SCF in the destruction of Med13 in cyclin C mediated cell death [Conference Abstract P2437, p. Monday 359-360]. *Molecular Biology of the Cell*. 2017 Dec 15;28(26):3727. doi: 10.1091/mbc.E17-10-0618. PMID: 29237772. PMCID: PMC5739290.

Authors

David C Stieg, Stephen D Willis, Joseph Scuorzo, Mia Song, Vidyaramanan Ganesan, Randy Strich, and Katrina F Cooper

P2437

Board Number: B587

The role of MAPK and SCF in the destruction of Med13 in cyclin C mediated cell death.

D.C. Stieg[1], S.D. Willis[1], J. Scuorzo[2], M. Song[2], V. Ganesan[1], R. Strich[1], K.F. Cooper[1];
[1]Molecular Biology, Rowan University Graduate School of Biomedical Sciences, Stratford, NJ, [2]Medicine, Rowan University School of Osteopathic Medicine, Stratford, NJ

In response to stress, the yeast [1] and mammalian [2] cyclin C translocate from the nucleus to the cytoplasm, where it associates with the GTPase Drp1/Dnm1 to drive mitochondrial fragmentation and apoptosis. Therefore, the decision to release cyclin C represents a key life or death decision. In unstressed cells, the cyclin C-Cdk8 kinase regulates transcription by associating with the Mediator of RNA polymerase II. We previously reported that that the Mediator component Med13 anchors cyclin C in the nucleus[3]. Loss of Med13 function leads to constitutive cytoplasmic localization of cyclin C, resulting in fragmented mitochondria, hypersensitivity to stress and mitochondrial dysfunction due to

loss of mtDNA. Recently we showed that this molecular switch operates in a two step process. First, efficient cyclin C nuclear release requires its ROS-induced phosphorylation by the MAP kinase Slt2 [4] in a carboxyl terminal region of cyclin C, which includes a putative Med13 interaction site. The second step involves ROS-induced Med13 destruction by the SCF^{Grr1} ubiquitin ligase. Med13 associates with Grr1 in two-hybrid assays, and SCF mediated degradation of Med13 requires active cyclin C-Cdk8[5]. However, phosphorylation of Med13 by cyclin C-Cdk8 does not trigger Med13 destruction. This suggests a model in which this kinase primes the Med13 degron for SCF^{Grr1} and either Slt2, or an as yet unidentified kinase, triggers its destruction. Taken together, these results are consistent with a model in which cyclin C phosphorylation by Slt2 permits its disassociation from Med13, and that Med13 destruction allows full cyclin C release and prevents re-accumulation of the cyclin in the nucleus.

[1]Dev. Cell. (2014), 28:161; [2]Mol. Biol. Cell. (2015), 26:1030; [3]Mol. Biol. Cell (2104) 25:2807; [4]Mol. Biol. Cell. (2014) 25:1396; [5]MB0C. (2017) submitted

Grant support: W.W. Smith Charitable Trust (CO 604) and NIH R15-113196 to K.F.C and NIH (CA099003 and GM086788) to R.S.